At the time of writing, the encouraging outcome of phase 3 clinical trials with CFTR modulators59–61 suggests that the early start of CFTR modulation may be the adequate preventive measure to acquire and retain a healthy airway metagenome in the CF airways. Here, CFTR is linked to cystic fibrosis.